San Diego, CA — March 4, 2026 — Leads & Copy — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, has announced that its President and Chief Executive Officer, Zachary Hornby, will participate in a fireside chat at the Leerink Global Healthcare Conference.
The fireside chat is scheduled for Wednesday, March 11, in Miami, Florida, at 11:20 a.m. ET. A live and archived webcast of the session will be accessible in the “Events & Presentations” section of Boundless Bio’s website, under Investors.
Boundless Bio is focused on developing cancer therapeutics, addressing the unmet needs of patients with oncogene amplified tumors. The company’s research centers on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class oral, selective degrader of Kinesin as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.
Boundless Bio is interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers.
Source: Boundless Bio
